Kite Pharma to Participate in Three Upcoming Investor Conferences in November 2014

Published 8:01 AM ET Wed, 5 Nov 2014
Globe Newswire

SANTA MONICA, Calif., Nov. 5, 2014 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Kite) (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today announced that members of the Company's management team will participate in three upcoming conferences in November 2014:

Tuesday, November 18, 2014, at 3:35pm Local Time The New York Palace Hotel, New York, New York Presenter: David Chang, MD, PhD, Kite's Executive Vice President, Research and Development, and Chief Medical Officer

Kite Pharma, Inc., is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a primary focus on eACT™ designed to restore the immune system's ability to recognize and eradicate tumors. In partnership with the NCI Surgery Branch through a Cooperative Research and Development Agreement (CRADA), Kite is advancing a pipeline of proprietary eACT™ product candidates, both CAR (chimeric antigen receptor) and TCR (T cell receptor) products, directed to a wide range of cancer indications. Kite is based in Santa Monica, CA. For more information on Kite Pharma, please visit www.kitepharma.com.